ReviewJCO global oncology2025
Emerging Trends in Point-of-Care Technology Development for Oncology in Low- and Middle-Income Countries.
Review in JCO global oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The growing cancer burden and suboptimal diagnostic capacity in low- and middle-income countries calls for urgent innovation in diagnostic solutions. Point-of-care technologies (POCTs) offer a transformative approach to decentralizing cancer diagnostics by providing rapid, affordable, and scalable testing in resource-constrained settings. Recent advancements, including loop-mediated isothermal amplification and multiplexed lateral flow immunoassay, enable high-sensitivity detection of cancer biomarkers without the need for complex laboratory infrastructure. Additionally, noninvasive imaging tools, such as optical coherence tomography and fluorescence-guided microscopy, offer portable and cost-effective solutions for early cancer detection in settings with limited health care services. These innovations are complemented by the integration of artificial intelligence, which improves diagnostic accuracy and reduces reliance on highly trained personnel. However, significant infrastructure and logistical challenges persist, including resource constraints, unreliable electricity, and insufficient cold-chain logistics, which limit diagnostic precision and accessibility. This review discusses recent advances in POCTs for oncology and examines how public-private partnerships and multisector collaborations can address key implementation barriers. By prioritizing inclusivity, cross-sector collaboration, and targeted investments, POCTs can sustainably narrow global disparities in cancer diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.